We are live on ! Find out more
BTW

Boston Trust Walden Portfolio holdings

AUM $13.1B
1-Year Est. Return 24.63%
This Fund
S&P 500
This Quarter Est. Return
+7.94%
1 Year Est. Return
+24.63%
3 Year Est. Return
+61.41%
5 Year Est. Return
+82.17%
10 Year Est. Return
+348.28%
AUM
$6.82B
AUM Growth
+$400M
Cap. Flow
-$64.1M
Cap. Flow %
-0.94%
Top 10 Hldgs %
17.87%
Holding
394
New
21
Increased
124
Reduced
197
Closed
10

Top Sells

Rank Stock Value
1
BCR
CR Bard Inc.
BCR
+$62.1M
2
CVS icon
CVS Health
CVS
+$18M
3
ACH
Accendra Health
ACH
+$14.8M
4
UI icon
Ubiquiti
UI
+$13.1M
5
EGBN icon
Eagle Bancorp
EGBN
+$11.4M

Sector Composition

Rank Sector Weight
1 Financials 19.36%
2 Healthcare 15.63%
3 Technology 15.4%
4 Industrials 13.63%
5 Consumer Discretionary 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ENSG icon
176
The Ensign Group
ENSG
$10.1B
$10.5M 0.15%
506,499
-14,570
-3% -$313K
EW icon
177
Edwards Lifesciences
EW
$47.6B
$10.5M 0.15%
279,909
-2,541
-0.9% -$93.3K
THRM icon
178
Gentherm
THRM
$1.31B
$10.5M 0.15%
330,288
-993
-0.3% -$34.4K
RMD icon
179
ResMed
RMD
$28.3B
$10.4M 0.15%
123,161
+5,308
+5% +$439K
ATRI
180
DELISTED
Atrion Corp
ATRI
$10.1M 0.15%
16,076
-230
-1% -$150K
SRCE icon
181
1st Source
SRCE
$2.07B
$10.1M 0.15%
204,544
-5,324
-3% -$270K
ST icon
182
Sensata Technologies
ST
$6.65B
$10.1M 0.15%
197,585
+4,928
+3% +$243K
BRO icon
183
Brown & Brown
BRO
$22.9B
$10.1M 0.15%
391,768
-5,186
-1% -$130K
MIDD icon
184
Middleby
MIDD
$6.05B
$10.1M 0.15%
74,632
+870
+1% +$106K
STE icon
185
Steris
STE
$20.9B
$10.1M 0.15%
114,911
+4,667
+4% +$416K
SBH icon
186
Sally Beauty Holdings
SBH
$1.4B
$10M 0.15%
533,377
-41,856
-7% -$725K
KAI icon
187
Kadant
KAI
$3.69B
$9.93M 0.15%
98,914
-1,957
-2% -$199K
AKAM icon
188
Akamai
AKAM
$16.8B
$9.71M 0.14%
149,380
-3,504
-2% -$194K
JNPR
189
DELISTED
Juniper Networks
JNPR
$9.71M 0.14%
340,831
-6,365
-2% -$172K
HMN icon
190
Horace Mann Educators
HMN
$2.1B
$9.58M 0.14%
217,253
-6,348
-3% -$277K
SIVB
191
DELISTED
SVB Financial Group
SIVB
$9.55M 0.14%
40,876
-206
-0.5% -$43.9K
IWM icon
192
iShares Russell 2000 ETF
IWM
$80.9B
$9.55M 0.14%
62,668
+49,596
+379% +$7.45M
IEX icon
193
IDEX
IEX
$16.5B
$9.43M 0.14%
71,439
+1,437
+2% +$185K
NTAP icon
194
NetApp
NTAP
$32.9B
$9.32M 0.14%
168,434
+2,108
+1% +$106K
EXPD icon
195
Expeditors International
EXPD
$22.9B
$9.16M 0.13%
141,526
+762
+0.5% +$46.7K
EWBC icon
196
East-West Bancorp
EWBC
$17.9B
$9.1M 0.13%
149,572
-10,201
-6% -$608K
CAC icon
197
Camden National
CAC
$924M
$9.09M 0.13%
215,663
-5,679
-3% -$247K
WRB icon
198
W.R. Berkley
WRB
$28B
$8.84M 0.13%
416,367
+11,131
+3% +$227K
SCI icon
199
Service Corp International
SCI
$11.4B
$8.55M 0.13%
229,177
+4,270
+2% +$153K
SYNT
200
DELISTED
Syntel Inc
SYNT
$8.53M 0.13%
370,986
-15,832
-4% -$375K

Similar funds

Boston Trust Walden's Q4 2017 Portfolio in Review

As of Q4 2017, Boston Trust Walden held 394 positions worth $6.82B, up 6.2% from $6.42B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Boston Trust Walden's Q4 2017 filing shows 21 new, 124 increased, 197 reduced and 10 closed positions. Its largest new stake was Charles River Laboratories: 122,536 shares worth $13.4M. The largest sale was CR Bard Inc., an estimated $62.1M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, down from 19% a quarter earlier, followed by Healthcare and Technology.

  • Boston Trust Walden's largest Q4 2017 buy was Charles River Laboratories: 122,536 shares worth $13.4M.
  • Boston Trust Walden added most to Becton Dickinson in Q4 2017, an estimated $14.8M increase.
  • Boston Trust Walden's biggest Q4 2017 reduction was CVS Health, cutting an estimated $18M.
  • Boston Trust Walden fully exited CR Bard Inc. in Q4 2017, selling an estimated $62.1M.
  • Boston Trust Walden's ten largest holdings make up 18% of its $6.82B portfolio in Q4 2017.
  • Boston Trust Walden opened 21 new positions and closed 10 in Q4 2017.
  • Boston Trust Walden's portfolio value rose 6.2% quarter-over-quarter to $6.82B.

Based on Boston Trust Walden's 13F filing for Q4 2017, filed 29 Jan 2018.